Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Completed

Conditions studied: Meningococcal Meningitis, Meningococcal Infections

In brief

To determine the persistence of protective antibody levels for subjects who seroconverted after vaccination with NmVac4-A/C/Y/W-135-DT™ Participants in trial # JN-NM-002, who seroconverted for serogroups A and C will be contacted and asked to provide a blood sample at 12-24 months after vaccination with NmVac4-A/C/Y/W-135-DT. Serum Bactericidal Assays will be performed to evaluated duration of protective antibody titer for NmVac4-A/C/Y/W-135-DT for all four serogroups. To determine if subjects who seroconverted with lower titers retain protective levels of antibody (titer ≥:8) at 12-24 months after vaccination.

Key facts

Study ID

NCT02500511

Run by

JN-International Medical Corporation

People needed

50

Starts

2015-06-01

Expected to finish

2015-09-01

Last updated by the study team

2016-04-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Willing and able to give informed consent
• Participant in trial JN-NM-002
• Seroconverted in trial JN-NM-002 for both serogroups A and C

You may not qualify if…

• Chronic medication use or medical history that, in the opinion of the Investigator, may impact the quality of the sample or safety of the subject

Where it is running

• IRC Clinics — Towson, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.